These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6357438)

  • 1. Effects of oxprenolol versus propranolol on myocardial performance and myocardial O2 consumption in hypertensive patients.
    Schlesinger Z; Ravid M; Meshulam R
    Cardiology; 1983; 70(4):199-205. PubMed ID: 6357438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic effects of oxprenolol and propranolol in hypertension.
    Franciosa JA; Johnson SM; Tobian LJ
    Clin Pharmacol Ther; 1979 Dec; 26(6):676-81. PubMed ID: 387330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Right ventricular performance in essential hypertension after beta-blockade.
    Ferlinz J; Easthope JL; Hughes D; Siegel J; Tobis J; Aronow WS
    Br Heart J; 1981 Jul; 46(1):23-9. PubMed ID: 7023516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of antihypertensive efficacy: propranolol versus oxprenolol in accelerated hypertension.
    Fernandez PG; Sharma JN; Galway AB; Kim BK; Granter S; Zachariah PK
    Pharmatherapeutica; 1982; 3(3):153-6. PubMed ID: 6752962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive and hemodynamic effects of oxprenolol versus propranolol.
    Ferlinz J; Easthope JL; Hughes D; Siegel J; Tobis J; Aronow WS
    Clin Pharmacol Ther; 1980 Jun; 27(6):733-43. PubMed ID: 6991196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oxprenolol on blood pressure, pulmonary ventilatory function and myocardial contractility in hypertensive patients.
    Schlesinger Z; Barzilay J
    Isr J Med Sci; 1980 Jun; 16(6):420-5. PubMed ID: 7399873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exercise performance in mildly hypertensive patients. Impairment by propranolol but not oxprenolol.
    Franciosa JA; Johnson SM; Tobian LJ
    Chest; 1980 Aug; 78(2):291-9. PubMed ID: 6995041
    [No Abstract]   [Full Text] [Related]  

  • 8. Antihypertensive effects of oxprenolol and propranolol.
    Materson BJ; Michael UF; Oster JR; Perez-Stable EC
    Clin Pharmacol Ther; 1976 Aug; 20(2):142-51. PubMed ID: 780037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension.
    Petrie JC; Jeffers TA; Robb OJ; Scott AK; Webster J
    Br Med J; 1980 Jun; 280(6231):1573-4. PubMed ID: 7000243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oxprenolol and propranolol on systolic time intervals.
    van Herick R; Aronow WS
    Clin Pharmacol Ther; 1978 Dec; 24(6):678-82. PubMed ID: 361333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.
    J Hypertens; 1985 Aug; 3(4):379-92. PubMed ID: 2864374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxprenolol and propranolol in anxiety states. A double-blind comparative study.
    Becker AL
    S Afr Med J; 1976 Apr; 50(16):627-9. PubMed ID: 772831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the effects of oxprenolol versus propranolol in essential hypertension.
    Gavras I; Gavras H; Sullivan PC; Tifft CP; Chobanian AV; Brunner HR
    J Clin Pharmacol; 1979 Jan; 19(1):8-14. PubMed ID: 368088
    [No Abstract]   [Full Text] [Related]  

  • 14. [Beta-blocking agents alone or combined with diuretics or alpha-adrenolytics in the treatment of essential arterial hypertension].
    Minutillo S; Lupinc V; D'Agnolo B
    Minerva Med; 1979 Dec; 70(57):3919-24. PubMed ID: 43488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial measurements of systolic time intervals during treatment with hydrochlorothiazide alone and combined with other antihypertensive agents.
    Kyle MC; Freis ED
    Am J Cardiol; 1985 Jan; 55(1):107-11. PubMed ID: 3966370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.
    Ferrara LA; Mancini M; Marotta T; Pasanisi F; Fasano ML
    Eur J Clin Pharmacol; 1986; 29(6):717-9. PubMed ID: 3519237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relative antihypertensive potency of propranolol, oxprenolol, atenolol, and metoprolol given once daily. A double-blind, crossover, placebo-controlled study in ambulatory patients.
    Ravid M; Lang R; Jutrin I
    Arch Intern Med; 1985 Jul; 145(7):1321-3. PubMed ID: 4015285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxprenolol in myocardial infarction survivors: brief review of the European Infarction Study results in the light of other beta-blocker post infarction trials.
    Schröder R
    Z Kardiol; 1985; 74 Suppl 6():165-72. PubMed ID: 2869616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pindolol and systolic time intervals in patients with hypertension.
    Hammond JJ; Kirkendall WM; Jacks-Nagle VL; Plotnick GD; Fisher ML; Hamilton JH; Robinson M; Carliner NH; Janoski AH; Hamilton BP
    Am Heart J; 1982 Aug; 104(2 Pt 2):456-64. PubMed ID: 7102532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotection by beta-blockers: molecular and structural aspects in experimental hypertension.
    Pauletto P; Vescovo G; Scannapieco G; Pessina AC; Dal Palù C
    Drugs Exp Clin Res; 1990; 16(3):123-8. PubMed ID: 1974839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.